A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer-Reference-Cited by-同舟云学术

A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer

Published:2012-09-06 Issue:1 Volume:136 Page:143-151
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Vardy J.,Pond G.,Dodd A.,Warr D.,Seruga B.,Clemons M.,Bordeleau L.,Goodwin P.,Tannock I. F.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-012-2205-3.pdf

Reference39 articles.

1. Hesketh PJ, Gralla RJ, du Bois A, Tonato M (1998) Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 6(3):221–227

2. Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20–28

3. Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13(2):80–84

4. Herrstedt J, Aapro MS, Roila F, Kataja VV (2005) ESMO minimum clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting (NV). Ann Oncol 16(Suppl 1):i77–i79

5. MASCC/ESMO Antiemetic Guideline (2011) [ http://data.memberclicks.com/site/mascc/MASCC_Guidelines_English_2011.pdf ]

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study;Bone Marrow Transplantation;2020-04-28

2. Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting;Breast Cancer Research and Treatment;2016-01

3. Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer – An inspection of the evidence base informing clinical decision-making;Cancer Treatment Reviews;2015-12

4. Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?;The Oncologist;2015-05-06

5. The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire–Chronic;Neuro-Oncology;2015-04-09